
Breaking Down the TRAILBLAZER-ALZ 2 Trial
0:00
10:27
In this episode, we explore donanemab, a groundbreaking monoclonal antibody treatment for Alzheimer's disease. We discuss its efficacy in reducing beta-amyloid plaques, unique treatment duration protocol, and safety considerations. Could this time-limited treatment approach revolutionize how we manage Alzheimer's progression?
Faculty: Scott Beach, M.D.
Host: Richard Seeber, M.D.
Więcej odcinków z kanału "Psychopharmacology and Psychiatry Updates"
Nie przegap odcinka z kanału “Psychopharmacology and Psychiatry Updates”! Subskrybuj bezpłatnie w aplikacji GetPodcast.